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lence of anxiety/depression in incident versus prevalent pa-
tients and the improvement over time may indicate an ame-
lioration of mood disorders after PH diagnosis and treat-
ment.  © 2016 S. Karger AG, Basel 
 Introduction 
 Pulmonary hypertension (PH) represents a group of 
rare disorders with a progressive course and a dismal 
prognosis if untreated  [1] . In the absence of relevant heart 
and lung diseases, the two major forms are pulmonary 
arterial hypertension (PAH) and chronic thromboem-
bolic PH (CTEPH). The majority of patients with CTEPH 
can be substantially improved or cured by surgical pul-
monary endarterectomy  [2, 3] . Since the availability of 
novel disease-targeted medical therapies, the prognoses 
for PAH and inoperable CTEPH have improved; how-
ever, these chronic disorders still cannot be cured. PH due 
to left heart disease and PH due to hypoxia/lung disease 
remain difficult to treat. PH-targeted treatment has so far 
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 Abstract 
 Background: Pulmonary hypertension (PH) leads to reduced 
health-related quality of life (HRQoL).  Objective: To investi-
gate the prevalence and course of anxiety and depression 
and their association with HRQoL, disease severity and sur-
vival in PH.  Methods: 131 PH patients (91 pulmonary arterial, 
30 chronic thromboembolic, 10 due to lung disease; 84 fe-
male, 47 male) had repeated assessments with the Hospi-
tal Anxiety and Depression Scale (HADS), HRQoL, six-minute 
walk distance and WHO functional class during a mean 
course of 16 ± 12 months.  Results: Among the 49 incident 
and 82 prevalent PH patients, the HADS score was positive 
in 53%/21% (depression), 51%/24% (anxiety) and 63%/26% 
(total score) (all p < 0.05). The HADS score was improved at 
the second assessment in incident patients. The HADS score 
correlated with HRQoL at all consecutive assessments and 
with functional class until the third assessment, but not with 
baseline hemodynamics, age or gender.  Conclusion: Mood 
disorders remain underdiagnosed in PH. The higher preva-
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not been found to improve symptoms nor to reduce mor-
bidity/mortality in these groups  [4, 5] .
 Due to unspecific initial symptoms, PAH diagnosis is 
usually delayed from the onset of symptoms between 1.5 
and 4 years  [6, 7] . This prolonged duration to diagnosis 
can lead to anxiety, depression and stress. After diagno-
sis the emotional burden persists along with initiation of 
complex therapies and potentially progressive physical 
impairment. Furthermore, patients often appear healthy 
at rest and thus might not be taken seriously by health 
care providers or their environment in their constrained 
daily life  [8] . Anxiety and depression are highly prevalent 
in chronic diseases and have also been commonly found 
in prevalent PAH patients under chronic therapy  [9–16] .
 In rare diseases, such as PAH or CTEPH, registries 
provide valuable information on the baseline characteris-
tics and outcomes of the disease  [17] . We have built a PH 
database in our daily practice, which includes classifica-
tion according to international guidelines  [18] , and have 
prospectively collected data according to standardized 
procedures, which allows long-term observation. In this 
database, we have also included several instruments for 
assessing health-related quality of life (HRQoL) and emo-
tional disorders by the Hospital Anxiety and Depression 
Scale (HADS)  [17] .
 In the REVEAL registry, a multicenter observational 
PAH cohort, 25% of patients reported symptoms of de-
pression, but these symptoms were not systematically as-
sessed by the questionnaire  [15] . Studies which conduct-
ed screening for depression with standardized instru-
ments, mainly self-administered questionnaires, found a 
prevalence ranging from 10 to 55%  [9–14] .
 The aim of the present study was to evaluate the prev-
alence of anxiety and depression in incident and hitherto 
untreated as well as in prevalent and pretreated patients 
with a diagnosis of mainly PAH or inoperable CTEPH, 
and to look for a correlation of the mood disorders with 
markers of disease severity, such as pulmonary hemody-
namics, exercise capacity and quality of life. Repeated as-
sessments of depression and anxiety after initiation of or 
during disease-targeted therapy were performed to study 
the course of these mood disorders and their correlation 
with symptoms.
 Methods 
 Study Subjects 
 All patients with PAH, CTEPH or other types of PH seen and 
diagnosed at our clinic gave their written informed consent to 
have their data registered  [17] . The local database of the PH center 
at the University Hospital of Zurich was reviewed for patients with 
PH who had filled in HADS questionnaires. Starting in 2012, this 
questionnaire has been handed to every PH patient at 0, 3, 6, 12 
and 24 months (newly diagnosed) or at every annual visit (treat-
ed). Precapillary PH was diagnosed by a mean pulmonary arterial 
pressure  ≥ 25 mm Hg, with a pulmonary artery wedge pressure 
 ≤ 15 mm Hg during right heart catheterization, and classification 
was made according to international guidelines, with all patients 
having ventilation-perfusion scan, pulmonary function test, rheu-
matologic assessment, thoracic angio-CT and/or pulmonary an-
giography  [1] . Incident patients were defined as patients who had 
filled in the HADS at the time of the diagnostic right heart cath-
eterization and were not yet receiving targeted therapy; the re-
maining patients were categorized as prevalent. The study was 
approved by the Zurich cantonal ethical review board (KEK 2014-
0592).
 Demographics, Exercise Performance, Anxiety and Depression 
Score and Quality of Life 
 During the initial diagnostic right heart catheterization, mean 
pulmonary arterial pressure, pulmonary vascular resistance, car-
diac index, as well as arterial and mixed venous oxygen saturation 
were noted. At the same time the patient’s demographics (age, sex, 
height, weight and calculated body mass index), medical history, 
WHO functional class and six-minute walk distance (6MWD) 
were assessed according to standard protocols. Between 2012 and 
2014, patients’ anxiety and depression was measured using the 
HADS questionnaire  [19] . The HADS is a fourteen-item question-
naire from which an anxiety and depression subscale can be de-
rived. Subscore values >5 points correspond to increased anxiety 
and/or depression, a total score >9 is pathological  [20] . It is con-
sidered a powerful tool for screening for symptoms of depression 
and anxiety, but has only rarely been used in PH  [21] . We used 
cut-offs that have recently been validated with regards to sensitiv-
ity and specificity in chronically ill COPD patients  [20] .
 HRQoL was assessed by the Minnesota Living with Heart Fail-
ure (MLHF) questionnaire (equaling the Living with Pulmonary 
Hypertension questionnaire). The MLHF questionnaire consists 
of a general score (range 0–105), a physical subscore (range 0–40) 
and an emotional subscore (range 0–25), with higher scores re-
flecting poorer quality of life. In addition, we used the Cambridge 
Pulmonary Hypertension Outcome Review (CAMPHOR) ques-
tionnaire specifically designed for PH, consisting of scales for 
symptoms (25 items), activity limitation (15 items) and quality of 
life (25 items), with a maximum score of 65 and likewise higher 
scores reflecting worse HRQoL  [22–24] .
 Statistical Analysis 
 Results are expressed as median (interquartile range) or mean 
± standard deviation according to non-normal or normal distribu-
tion (tested by the Kolmogorov-Smirnov test). The non-paramet-
ric Mann-Whitney U test was used to compare two independent 
samples; differences in the course of the disease were calculated 
using the Wilcoxon test. Fisher’s exact test was used to compare 
frequencies of mood disorders in incident and prevalent patients. 
Survival was estimated using the Kaplan-Meier method with the 
Breslow test (generalized Wilcoxon). Factorial analysis was used to 
build a composite factor of the various related HRQoL parameters 
and the three HADS parameters. A p value <0.05 was considered 
statistically significant.
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 Results 
 Baseline Characteristics 
 A total of 131 patients were included. Most of the pa-
tients (66%) were diagnosed with PAH, the second largest 
group (23%) consisted of CTEPH patients (inoperable or 
persistent after pulmonary endarterectomy). We also in-
cluded small groups with severe PH due to lung disease 
or multifactorial origin.
 The patients’ characteristics at the time of PH diagno-
sis are shown in  table 1 , which consisted with the time of 
the first HADS in 37% of patients (incident group). 63% 
of patients had received PAH-targeted medical treatment 
for a mean time of 36 (15–74) months before the screen-
ing test for depression and anxiety was performed (prev-
alent group). At the time of analysis, these prevalent pa-
tients were treated with the following PAH-targeted ther-
apies: endothelin receptor antagonist (60%), phosphodi-
esterase type 5 inhibitor (44%), soluble guanylate cyclase 
stimulator (8%), or prostanoids (21%); 36% were on com-
bination therapy and 13% with CTEPH underwent pul-
monary endarterectomy.
 Most of the patients were in WHO functional class III 
(43%) at the time of first HADS screening and had a me-
dian 6MWD of 480 m (375–545) at a mean age of 67 years 
(51–75).
 Quality of life measured by the MLHF questionnaire 
and the CAMPHOR questionnaire was reduced (corre-
sponding to high scores;  table 2 ), but better (correspond-
ing to lower scores) in prevalent patients under therapy 
compared to incident patients.
 Prevalence of Depression and Anxiety 
 Overall, the median HADS score for depression was 3 
(2–7) and that for anxiety was 4 (2–7); the total score was 
7 (4–14). In 46% of patients either anxiety, depression or 
total scores were elevated, revealing symptoms consistent 
with a diagnosis of depression or anxiety mood disorder. 
More than one third of patients had elevated subscores 
(>5), and 40% had a total HADS score >9. During initial 
questionnaire screening, incident patients had higher 
HRQoL and HADS scores, meaning that they perceived 
their HRQoL and their mental health as worse than the 
group of prevalent patients.
 Table 1.  Patients’ baseline characteristics
Patients’ characteristics n (%) or 
median (IQR)
Incident 
patients
Prevalent 
patients
Total number of patients 131 (100%) 49 (37%) 82 (63%)
Females/males 84/47 (64%/36%)
Age, years 67 (51 – 75) 67 (47 – 76) 67 (55 – 74)
Body mass index 25 (21.5 – 28.0) 26 (23.0 – 30.0) 25 (21.0 – 27.0)
PH classification
PAH 91 (70%) 38 (78%) 53 (65%)
Idiopathic 72 (55%) 29 (59%) 43 (52%)
Associated with connective tissue disease 10 (8%) 5 (10%) 5 (6%)
Associated with portal hypertension 4 (3%) 3 (6%) 1 (1%)
Associated with HIV infection 1 (1%) 0 (0%) 1 (1%)
Associated with congenital heart disease 4 (3%) 1 (2%) 3 (4%)
Severe PH due to lung diseases 10 (8%) 4 (8%) 6 (7%)
CTEPH 30 (23%) 7 (14%) 23 (28%)
Baseline hemodynamics
Heart rate, bpm 78 (69 – 89) 79 (72 – 87) 77 (69 – 90)
Mean pulmonary artery pressure, mm Hg 40 (32 – 51) 35.5 (28 – 49) 42 (34 – 54)*
Cardiac index, liters/min/m2 2.8 (2.3 – 3.4) 3 (2.0 – 3.7) 2.7 (2.0 – 3.2)**
Right atrial pressure, mm Hg 8 (5 – 10) 8 (6 – 12) 8 (5 – 10)
Wedge pressure, mm Hg 12 (9 – 14) 12 (10 – 14) 12 (8 – 14)
Arterial oxygen saturation, % 92 (88 – 95) 91 (88 – 95) 92 (88 – 95)
Mixed venous oxygen saturation, % 65 (60 – 72) 63 (60 – 72) 67 (60 – 72)
 HIV = Human immunodeficiency virus; IQR = interquartile range.
* p < 0.05; ** p < 0.01.
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 Pre-Diagnosed Mood Disorders 
 15.3% of our patients (n = 20) had previously been di-
agnosed with and treated for anxiety or depression at the 
time of the first questionnaire screening. These patients 
had a median of 7 (3–9) in the anxiety, 8 (3–9) in the de-
pression and 15 (7–18) in the total score. Patients without 
mood disorders revealed median scores of 3 (2–6) in anx-
iety, 3 (2–6) in depression and 7 (4–11) in total score. Of 
the patients who were found to be depressed and/or anx-
ious according to HADS (n = 60, 46%), 23% (n = 14) were 
under treatment, meaning that >75% were not on antide-
pressant/anxiolytic therapy. In the collective of patients 
with mental disorders diagnosed by HADS, patients with 
pre-diagnosed mental comorbidities had worse HADS 
scores, indicating insufficient therapy.
 HADS Time Course 
 Eighty patients (61%; 33 incident, 47 prevalent) had 
filled in the HADS at least twice. Patients who had been 
screened as depressed/anxious in their first HADS dem-
onstrated two troughs in their HADS score time course, 
with an initial improvement of mental symptoms fol-
lowed by a transient slight worsening and late improve-
ment with prolonged follow-up ( fig.  1 ). The first im-
provement of the total score was significant in incident 
and prevalent patients, the improved depression subscore 
was only significant in the incident group (from 8.0 ± 3.5 
to 5.0 ± 4.0, p = 0.001), whereas the improved anxiety 
score was only significant in the prevalent group (from 
7.5 ± 3.5 to 6.5 ± 5.0, p = 0.021). Patients who had normal 
HADS scores at the beginning remained stable or even 
improved during follow-up. Prevalent patients had a 
trend towards worsening of symptoms at the end of our 
observation time. Between the second and the third 
HADS assessment, the worsening of total HADS score 
was significant in prevalent patients.
 Table 2. Baseline assessment of symptoms, walk distance, non-invasive hemodynamics, anxiety, depression and 
quality of life in incident and prevalent PH patients
 n (%) or median (IQR)
all p atients 
(n = 131)
incident patients 
(n = 49)
prevalent patients 
(n = 82)
WHO functional class 3 (2 – 3) 3 (2 – 3) 2 (2 – 3)**
I/II 58 (44.2%) 13 (26.5%) 45 (54.9%)
III 56 (42.7%) 26 (53.1%) 30 (36.6%)
IV 15 (11.5%) 10 (20.4%) 5 (6.1%)
6MWD, m 480 (375 – 545) 435 (311 – 509) 484 (412 – 552)*
SpO2 after 6MWD, % 90 (84 – 94) 90 (85 – 95) 90 (82 – 94)
Tricuspid pressure gradient (echo), mm Hg 59 (39 – 79) 62 (46 – 78) 50 (31 – 83)
LHFQ general, points 27 (13 – 47) 43 (24 – 57) 21 (10 – 38)**
LHFQ physical, points 15 (8 – 22) 21 (12 – 26) 13 (6 – 20)**
LHFQ emotional, points 4 (1 – 11) 10 (5 – 17) 3 (0 – 8)**
CAMPHOR activity, points 7 (3 – 12) 11 (7 – 15) 5 (2 – 9)**
CAMPHOR symptoms, points 6 (3 – 10) 8 (5 – 11) 5 (2 – 9)*
CAMPHOR quality of life, points 3 (1 – 7) 6 (2 – 12) 1 (0 – 5)**
HADS screening started, months after baseline 11 (0 – 46) 0 (0 – 1) 36 (15 – 74)**
HADS depression, points 3 (2 – 7) 6 (3 – 9) 3 (1 – 5)**
HADS anxiety, points 4 (2 – 7) 6 (3 – 9) 3 (2 – 5)**
HADS total, points 7 (4 – 14) 11 (7 – 17) 6 (3 – 10)**
Patients with HADS depression >5 43 (33%) 26 (53%) 17 (21%)#
Patients with HADS anxiety >5 45 (34%) 25 (51%) 20 (24%)#
Patients with HADS total >9 52 (40%) 31 (63%) 21 (26%)#
All values account for the time of the first HADS assessment.
IQR = Interquartile range; LHFQ = Living with Heart Failure Questionnaire; SpO2 = peripheral oxygen 
saturation.
* p < 0.05; ** p < 0.01; # Fisher’s exact test < 0.01.
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 Correlation and Regression Analysis 
 HADS correlated well with HRQoL overall consecu-
tive assessment and with WHO functional class until the 
third assessment ( table 3 ). However, HADS did not cor-
relate with the 6MWD or other parameters such as age, 
body mass index or hemodynamics. HRQoL correlated 
with the 6MWD until the third consecutive questionnaire 
assessment ( table 3 ).
 Transplant-Free Survival 
 There was no difference in overall transplant-free sur-
vival between prevalent and incident patients. However, 
depressed patients (according to the first HADS depres-
sion subscore) had worse overall survival than non-de-
pressed patients with a Breslow value of 0.006 ( fig. 2 ).
 Discussion 
 The results of our study indicate that over one third of 
PH patients suffer from depression and/or anxiety, with 
a higher prevalence in incident compared to prevalent
patients. Together with the improvement over time, our 
data may indicate that PH diagnosis, initiation of treat-
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c d
 Fig. 1.  a Incident patients with abnormal HADS scores.  b Prevalent 
patients with abnormal HADS scores.  c Incident patients with nor-
mal HADS scores.  d Prevalent patients with normal HADS scores. 
Abnormal: subscore (anxiety, depression) >5, total >9. Time 1: 
baseline; time 2: 3 months; time 3: 6 months; time 4: 12 months. 
Significant improvement [6 (4–10) months after filling in the first 
questionnaire] of the total HADS score in prevalent and incident 
patients with precapillary PH is seen, as well as improvement of the 
anxiety subscore in prevalent patients (from 7.5 ± 3.5 to 6.5 ± 5.0, 
p = 0.021) and of the depression subscore in incident patients 
(from 8.0 ± 3.5 to 5.0 ± 4.0, p = 0.001) from the first to the second 
HADS assessment. 
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ment and regular follow-up at a PH center can improve 
patients’ mental symptoms, along with an increased qual-
ity of life. Anxiety and depression correlate with WHO 
functional class and HRQoL, and depressed patients have 
a worse outcome.
 Several studies have shown that depression and anxi-
ety are frequently reported symptoms in PH  [9–12, 14] , 
and thus screening for mental disorders has been recom-
mended  [25, 26] .
 The prevalence of depression in studies performed in 
either PH or PAH patients with self-administered ques-
tionnaires varies from 10 to 55%, with the majority rang-
ing around 35%. Anxiety prevalence ranges from 9 to 21% 
of patients  [10, 12, 21] . However, one of those studies 
used higher score cut-offs than the ones we employed and 
thus possibly missed some anxious patients.
 Although the overall medians of the anxiety and de-
pression subscores and the total HADS score were not el-
evated compared to the general population  [27, 28] , we 
found elevated HADS scores in 46% of patients overall, 
with a significantly higher percentage of mood disorders 
in incident versus prevalent patients. Overall, less than 
one fourth of patients with mood disorders according to 
HADS were treated for their depression or anxiety. These 
data point towards underestimation of mental symptoms 
by health care providers. A recent study found a normative 
value for anxiety of 6 (4–9) for women and 5 (2–8) for men 
as well as a depression score of 3 (1–6) for both men and 
women  [27] . In another study in a healthy German popu-
lation, 21 and 23% had elevated anxiety and depression 
scores, respectively, although the authors used a higher 
cut-off of  ≥ 8 and did not look at the total score  [28] . In a 
previous study which used the Depression Anxiety Stress 
Scale (DASS), it was found that 22% of PAH patients had 
abnormal scores and were receiving psychopharmacolog-
ical treatment  [13] ; thus, this study found a frequency of 
mood disorders in PAH which was comparable to that of 
the normal population. Other studies report varying re-
sults from 8 to 32% of treated mentally disordered patients 
with the use of different types of questionnaires  [9–11] . In 
our study, patients previously diagnosed and treated for 
mood disorders had worse HADS scores than patients 
without psychopharmacological treatment. This indicates 
that their mood disorder is undertreated, an unsatisfac-
tory fact that has been previously described in PH  [10–12] .
 Both incident and prevalent patients revealed an im-
provement in total HADS score from the first to the second 
assessment, albeit this was more pronounced in incident 
patients. The reason for this improvement might be mul-
tifactorial; the mere handling out of questionnaires, the 
initiation or change in supportive care or medical therapy, 
the natural course of mood disorders, or other patient- or 
environment-related factors might have played a role.
 Table 3. Correlation coefficients of HADS and HRQoL scores
6MWD 
(n = 128)
HRQoL 
(n = 128)
WHO functional 
class (n = 129)
6MWD
HADS1 (n = 131) –0.145 0.763** 0.414** HRQoL1 –0.383**
HADS2 (n = 80) 0.048 0.738** 0.296** HRQoL2 –0.273*
HADS3 (n = 49) –0.041 0.801** 0.39** HRQoL3 –0.297*
HADS4 (n = 23) –0.21 0.74** 0.261 HRQoL4 –0.39
All measurements correspond to the time of HADS1/2/3/4.
* p < 0.05; ** p < 0.01.
Number at risk
Depression (42)
No depression (87)
1.0
0.8
0.6
0.4
0.2
0
0 365
Time (days)
730 1,095
19 5 0
61 23 4
Cu
m
ul
at
iv
e 
su
rv
iv
al
+ + ++++ + ++++++ +++++ ++++++++
++ + ++ + +++
+++ + ++++++ +
++++
+ ++ ++ + ++++ ++ +
 Fig. 2. Kaplan-Maier curve of the survival of depressed (HADS 
depression >5) versus non-depressed patients. 
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 HRQoL and HADS scores assessed in prevalent patients 
during the course of the disease revealed better scores but 
worse resting hemodynamics at initial invasive diagnosis 
than in incident patients. A potential explanation for the 
worse hemodynamics in prevalent patients might be that 
PH was diagnosed at a later stage in earlier years. The find-
ing that HADS and HRQoL scores were better and the fre-
quency of mood disorders significantly less in prevalent 
compared to incident patients points towards a positive 
effect of treatment and/or follow-up in a specialist center. 
Incident patients had improved scores 3–6 months after 
initiation of medical treatment. Thus, this is the first report 
on a favorable course of mental disorders under supportive 
care and PAH-targeted medical therapy. An additional 
reason for the improvement in mood might also be the fact 
that patients were relieved as they finally got diagnosed 
with the disease after a sometimes long duration of symp-
toms and uncertainty. PH is a disease that usually has a 
long latency period, with a high level of suffering before the 
diagnosis is definite  [6] . Patients may have also adapted to 
coping strategies with the disease after confirmation of the 
diagnosis. Care at a specialist PH center with expert physi-
cian and nurse counselling and access to patients peer 
groups might also help to improve patients’ mood. The dif-
ferential impact of drug therapy, health provider support 
or patients’ own coping strategies cannot be defined ac-
cording to our study, but would be helpful and important 
to know for health care providers in order to offer the best 
strategy to support their patients in achieving not only bet-
ter functional capacity and exercise performance, but al-
so less mood disorders. Our data support a transient im-
provement of mental disorders by modern PH treatment 
along with improvements in functional class and HRQoL 
 [29–32] . In an ethnographic study by Kingman et al. pub-
lished in 2014  [33] , PH patients were divided into solu-
tion seekers and disease-dominated. Comparing these two 
strategies shows that a patient can better cope if he is a so-
lution seeker. With patient education, knowledge about 
the disease and group support, a disease-dominated pa-
tient could maybe turn into a solution seeker.
 The findings of a worse survival in patients with el-
evated depression scores and the sustainably elevated 
HADS scores indicate the need for psychiatric and/or 
psychological support and counselling for PH patients, 
potentially along with psychiatric drug therapy in order 
to improve mental symptoms in this collective. PH clinics 
often try to establish such support, and psychological 
support is recommended in the current PH guidelines 
with an evidence level of 1c  [34] . However, financial re-
straints might limit adequate support for mental disor-
ders. The finding that patients who are depressed accord-
ing to HADS have a worse survival is remarkable and the 
reason for this finding is not clear. It might well be that 
patients with worse functional parameters and hemody-
namics tend to be more depressed. We found that an in-
creased HADS score correlated with worse HRQoL, one 
of the most relevant outcome parameters. However, 
HADS scores were not correlated with the 6MWD, de-
spite a good correlation of HRQoL with the 6MWD. This 
may indicate that only measuring HRQoL and 6MWD 
might not be enough to evaluate patients’ mental health: 
some patients might be depressed or anxious despite a 
preserved 6MWD – usually more active people who are 
subjectively seriously limited despite an objectively mea-
sured walk distance within the suggested therapeutic 
goals  [34] . However, the different characters and coping 
strategies of patients might also play a remarkable role.
 The limitations of our study are the decreasing num-
ber of patients during follow-up and the fact that neither 
the incident nor the prevalent patient groups are homo-
geneous, as patients present with different disease stages 
and have different disease courses at diagnosis and during 
follow-up. We do not know either for how long patients 
with pre-diagnosed mood disorders had been treated for 
their anxiety or depression and whether this time period 
would have correlated with their diagnosis of PH.
 In conclusion, psychological morbidity remains un-
derdiagnosed in precapillary PH. Almost half of patients 
suffer from depression and/or anxiety, for which only 
23% are treated. The slightly lower prevalence of mood 
disorders in prevalent compared to incident patients 
might point towards a favorable effect of supportive and 
PAH-targeted medical therapy.
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